Entera Bio Ltd. has announced the appointment of Dr. Juan Camilo Arjona Ferreira to its Board of Directors, effective December 1, 2026. This strategic move is designed to bolster the company's leadership in the biological products sector, particularly in women's health. Dr. Arjona Ferreira's extensive experience in clinical development is expected to enhance Entera's capabilities as it advances its innovative oral peptide therapies.

Dr. Arjona Ferreira, who currently serves as Head of Research & Development and Chief Medical Officer at Organon & Co., brings over two decades of experience in clinical development and regulatory execution. His expertise aligns with Entera's focus on developing treatments for significant unmet medical needs, including osteoporosis and hypoparathyroidism.

Background

Entera Bio Ltd. is a clinical-stage company based in Jerusalem, Israel, specializing in the development of oral peptide and protein replacement therapies. The company operates under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products (no diagnostic substances). Entera is listed on the Nasdaq under the ticker symbol ENTX.

Recent filings show that Entera has been actively engaged in corporate governance and strategic planning. The latest filing, dated October 27, 2026, includes significant updates regarding board appointments and departures.

What the Filing Says

The recent SEC filing states, "On October 27, 2026, the Board of Directors of Entera Bio Ltd. appointed Juan Camilo Arjona Ferreira, M.D., as a Class II director of the Company, effective December 1, 2026." The filing also notes that Dr. Arjona Ferreira will serve on the compensation committee of the Board.

Additionally, the filing indicates that Haya Taitel will step down from her position as a director, effective the same day. The filing clarifies that her departure was not due to any disagreement with the company's operations or policies.

Impact

Dr. Arjona Ferreira's appointment is expected to positively impact Entera Bio's strategic direction, particularly in enhancing its focus on women's health. His background in clinical development at major pharmaceutical companies like Organon, Myovant, and Merck positions him as a valuable asset to the Board. This change may also influence Entera's relationships with stakeholders in the biological products industry, as the company continues to innovate in its field.

What's Next

The filing does not specify what happens next regarding further board changes or strategic initiatives. However, the appointment of Dr. Arjona Ferreira is likely to be followed by ongoing developments in Entera's product pipeline and corporate governance.